Topical Analgesics Emerge as Important Pain-Management Tools

Estimates from the Centers for Disease Control and Prevention (CDC) show that more than 50 million individuals in America experienced chronic pain in 2021. Chronic pain is a common reason for patients to seek medical care. It can significantly impact an individual’s daily life as well as overall quality of life in the long-term, which makes its treatment crucial.

Currently, opioids are commonly prescribed to help manage chronic pain. It is estimated that roughly 20% of patients who suffer from persistent pain are prescribed opioids. With the current opioid crisis affecting states across America and the fact that prescribed opioids make up a good fraction of all overdoses, alternatives to manage chronic pain are needed.

An effective alternative treatment for pain management is analgesics, which are available over the counter as well as in prescription form.  The effectiveness of analgesics has been proven in numerous studies. For instance, one study from 2010 that involved testing the effectiveness of 3% 1-menthol patch and 10% methyl salicylate in managing chronic pain determined that the intensity of pain considerably decreased for patients who used the patch.

The study’s findings supported the approval of the first over-the-counter topical analgesic patch by the FDA. Topical analgesic safety has also been proven, with researchers noting that topical agents are safer due to their decreased risk for drug-to-drug interactions and adverse events.

So, how do analgesics work?

Topical analgesics provide a localized therapy option without possible side effects linked to other conventional treatments of chronic pain. These drugs penetrate the epidermis, offering local relief.  A commonly used topical drug is lidocaine, which is prescribed for neuropathic and musculoskeletal pain management.

Professional and medical societies also recommend the use of topical analgesics in managing chronic pain. For instance, the Osteoarthritis Research Society International published guidelines in 2019 that strongly recommended topical nonsteroidal anti-inflammatory drugs for knee osteoarthritis. It also recommended these drugs for patients with cardiovascular and/or gastrointestinal pain, particularly in cases where nonselective use of nonsteroidal anti-inflammatory drugs is restricted.

That same year, the American College of Rheumatology published guidelines for treating osteoarthritis and recommended localized therapy.

The following year, the American Academy of Family Physicians and the American College of Physicians released guidelines for managing pain from musculoskeletal injuries. They recommended the use of topical NSAIDS to alleviate pain and improve physical functioning.

It should be noted that guidelines from theses organizations prioritizing the use of topical analgesics over opioids align with recommendations made by the CDC.

Companies such as SOHM Inc. (OTC: SHMN) are also working to make even more analgesics readily available so that those who would be better served by these topical alternatives use them in lieu of opioids.

NOTE TO INVESTORS: The latest news and updates relating to SOHM Inc. (OTC: SHMN) are available in the company’s newsroom at https://ibn.fm/SHMN

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Archives

Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050